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Abstract Drooling (saliva loss) is a frequently reported
symptom in patients with Parkinson’s disease (PD), but an
accurate estimate of the prevalence of drooling is lacking.
The aim of this study was to systematically review the
prevalence of drooling in published research papers. A
systematic PubMed and CINAHL search was done, includ-
ing studies published until January 2009. Eight studies were
found, presenting prevalence rates of drooling based on
responses of PD patients to questionnaires. The statistical
heterogeneity was highly signiﬁcant (P\0.0001), with
prevalence rates ranging from 32 to 74%. The pooled
prevalenceestimatewith randomeffectanalysiswas of56%
(95% CI 44–67) for PD patients and 14% (95% CI 3–25) for
healthy controls; the pooled relative risk (RR) with random
effect analysis was 5.5 (95% CI 2.1–14.4). All studies
reporteddataofcommunitydwellingidiopathicPDpatients,
with a mean age around 65 years and mild PD in 50–60% of
the cases. Heterogeneity was mainly caused by differences
in deﬁnition or frequency of drooling. The highest preva-
lence rates included nocturnal drooling where others noted
only diurnal drooling. Analysis of the data of two studies
showed that drooling is reported frequently by 22–26% of
the patients. Prevalence rates were lower in milder PD
patients.Thesummarizedﬁndingsdemonstratethatdrooling
can be present in half of all PD patients. In about a quarter of
PD patients, drooling appears to be a frequently occurring
problem.We recommend to report droolinginfuturestudies
with more detailed consideration of severity, frequency and
nocturnal versus diurnal complaints.
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Deﬁnition
Introduction
Parkinson’s disease (PD) is present in about 0.3% of the
populationandischaracterizedbybothmotorandnon-motor
symptoms [2, 15]. Speech-language therapists are involved
with the oral-motor disorders in PD, such as speech
impairments,swallowingdisordersandincreasinglyalsothe
issue ofdrooling. Drooling, deﬁned as aninvoluntaryloss of
saliva, is an embarrassing problem with a serious impact on
socialfunctioning[11].However,itisunclearhowmanyPD
patients experience drooling and to what extent. Published
estimates of the prevalence of drooling vary considerably,
from 30 up to 74% [3, 16]; the highest estimate would be
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which is estimated at about 70% [8, 14]. A more accurate
approximation of the prevalence of drooling is currently
missing, including clarity about the deﬁnition of drooling
and association with disease duration and severity. The aim
of this study was to systematically review studies reporting
the prevalence and severity of drooling in PD.
Methods
A literature search was conducted by the ﬁrst author in
PubMed and Cinahl in January 2009 with the following
search terms: [‘‘Parkinson Disease’’ (MESH) or ‘‘Parkin-
sonian Disorders’’ (MESH)] and [‘‘Sialorrhea’’ (MESH) or
‘‘Salivation’’ (MESH) or ‘‘Drooling’’ (tw) or ‘‘Saliva’’
(tw)]. A second search was done to ﬁnd eligible studies
concerning the investigation of more general PD com-
plaints possibly including drooling, using [‘‘Parkinson
Disease’’ (MESH) or ‘‘Parkinsonian Disorders’’ (MESH)]
and [‘‘Gastrointestinal Diseases’’ (MESH) or ‘‘Autonomic
Nervous System Diseases’’ (MESH) or ‘‘Nonmotor’’ (tw)]
as search terms.
Articles were considered eligible when: (1) the results
provided an estimate of the prevalence of drooling in a
population-based study of patients with PD or atypical
Parkinsonism (only if clearly stated), (2) the results were
published as an article, not as an abstract, and (3) the
deﬁnition or method to ascertain drooling was described.
No language limitations were used. Study selection was
done independently by the ﬁrst author (JGK) and second
author (BdS). In addition, the ﬁrst author checked refer-
ences in review articles and studies on the treatment of
drooling that were published between 2000 and 2008.
The following data were extracted from the included
studies:
• patient recruitment and study sample (patients and
controls)
• patient and disease characteristics: age, disease dura-
tion, disease severity and speciﬁc diagnosis (idiopathic
PD or atypical parkinsonism)
• deﬁnition and identiﬁcation of drooling
• drooling rate in the studied patients (and controls)
• correlation between drooling and disease severity and
disease duration
All data were summarized in one table to study clinical
heterogeneity.
Statistics
Statistical heterogeneity was evaluated, and an estimate of
the pooled prevalence for patients and controls and the
overall risk ratio were computed with a random effect
model to account for between-studies variation [5].
Results
The initial search strategies revealed 111 articles, of which
only one met the selection criteria [16]. The second search
revealed 1,624 articles, of which 6 met the inclusion cri-
teria [1, 4, 8, 13, 17, 19]. Reference tracing exposed a
further study [3]. Two other studies that were also found
via reference tracing [9, 10] were excluded because they
were only published as an abstract; therefore, the available
data were incomplete for this review. A comparable search
in CINAHL did not reveal additional studies.
Hence, eight studies met all inclusion criteria. All rele-
vant data are summarized in Table 1. In all studies the data
on drooling were extracted from the results of question-
naires: two studies investigated drooling as part of
gastrointestinal symptoms in PD [3, 4], two other studies as
part of autonomic dysfunction—although the authors
acknowledge that drooling is not a sign of autonomic dys-
function[17, 19]—and two further studies as part of non-
motor symptoms in PD [1, 13]. One study had speech and
swallowing in PD as the main focus [8], and one study
reported gender differences for the most frequent PD
symptoms [16]. We found no studies that merely and spe-
ciﬁcally addressed the prevalence of drooling in PD. None
of the studies included patients with atypical Parkinsonism.
The eight studies reported the prevalence of drooling in
clinically approximately comparable populations of con-
secutive community-dwelling PD patients, with a mean age
around 65 years and mild PD in 50–60% of the cases
(Table 1). However, statistical heterogeneity was highly
signiﬁcant (P\0.0001), with prevalence rates ranging
from 32 to 74% (Fig. 1). The pooled prevalence estimate
with random effect analysis was of 56% (95% CI 44–67)
for PD patients and 14% (95% CI 3–25) for healthy con-
trols. The pooled relative risk (RR) with random effect
analysis was 5.5 (95% CI 2.1–14.4).
The deﬁnitions of drooling vary widely, ranging from the
broad description of ‘‘ever dribbling of saliva’’ to more
precise characterizations such as ‘‘dribbling of saliva during
the daytime, experienced during the last month.’’ The
methods used to obtain responses to the questionnaires also
varied. One study used different severities to scale the
answers [17], four studies used a ‘yes/no’ response [1, 3, 13,
16], and three studies used an adjective frequency scale, but
onlytwo(partly)reportedpercentagesperscaleitem [8,19].
The percentages per frequency item in the latter studies
revealedthat36%[8]and51%[19]experiencelossofsaliva
‘seldom’ or ‘sometimes,’ while a quarter of patients (26 and
22%) reported drooling ‘often’ or ‘frequently’ (Table 1).
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123Correlationofdroolingwithdiseaseseveritywasreported
infourstudies.Threeofthemfoundapositiveandsigniﬁcant
correlation with drooling as a single complaint [3, 19]o r
drooling as part of the digestive complaints [13]. One study
found that gastrointestinal complaints (including drooling)
did not increase with disease duration or severity, but a
correlation with single items was not reported [17]. Gender
differences were investigated in three studies. Two reported
signiﬁcantly higher drooling rates in men than in women
[1, 16], and one did not ﬁnd a gender difference in digestive
complaints, but single items were not reported [13].
Discussion
The results of this systematic review reveal that in a
community-based population of PD patients, about half of
the patients experiences drooling, while in a quarter of
patients drooling occurs often. The relative risk of drooling
problems is more than ﬁve times higher in comparison with
healthy controls. Despite an intensive search strategy, only
eight studies were found with useful data, but we
acknowledge that additional relevant reports on prevalence
rates might have been missed because this kind of study is
poorly indexed. However, since the search did not reveal
any studies focusing primarily on drooling in PD, publi-
cation bias seems unlikely, and this corroborates the
internal validity of this present review.
The large differences between the studies (heterogene-
ity) may be explained as follows. The three studies with the
highest prevalence rates (70% and more) may have over-
estimated the prevalence of drooling. The study reporting
the highest rate of 74% [3] was also the oldest (1965). It
could be argued that this high prevalence might be caused
by the fact that PD patients in those days were not yet
receiving adequate anti-parkinson medication, because
treatment with levodopa only started to become usual after
1967 [6]. However, in the other two studies reporting high
prevalence rates, 80–90% of patients used anti-parkinson
medication, emphasizing that the prevalence is also con-
siderable in patients using medication, although ‘levodopa
phobia’ might keep many PD patients on low dosages
unjustly [7, 12]. The high rate in the Verbaan study consists
of 51% of patients who reported to have this complaint
only ‘sometimes.’ The 73% prevalence rate may be further
clariﬁed by having included nocturnal drooling. Verbaan
et al. [19] and also Martinez-Martin et al. [13] and Cheon
et al. [1] asked for ‘‘dribbling of saliva during the last
month,’’ but the latter two studies used the PD NMSQuest
in which ‘‘during the daytime’’ is added. This might
explain the lower prevalence rates of 32–42%. The 70%
rate in the Edwards study might be clariﬁed likewise, but
data on frequency of saliva complaints or diurnal versus
nocturnal drooling were not reported.
A positive correlation between drooling complaints and
diseaseseveritywasreportedinthreestudies,suggestingthat
drooling is more commonly present in more severely affec-
tedpatients.Thisisinagreementwiththeﬁndingthatthetwo
studies reporting the lowest prevalence rates (42–32%) had
the smallest number of severely affected PD patients (0–
9%);hencetheseﬁguresmightrepresentanunderestimation.
Additionally, none of the studies included PD patients in
nursinghomes,leavingouttheseverelyadvancedHoehnand
Yahr stage 5 patients, with probably the highest prevalence
ofseveredrooling.Takentogether,theprevalenceinthetotal
PD population might be higher than 56%.
Unlike dysarthria or dysphagia, drooling is difﬁcult to
examine. Saliva production can be measured, but clinical
Fig. 1 Forest plot
demonstrating the prevalence
rates of drooling with the 95%
conﬁdence intervals of eight
studies. The circle size
represents the sample size. The
overall rate, calculated with
random effect analysis is 56%
(95% CI 44–67)
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123experience dictates that dribbling of saliva in PD patients
during professional consultation is only visible in very
severe cases, so observation is typically insufﬁcient. Con-
sequently, this ﬁnding is fully based on the subjective
response of patients (or caregivers) to questions and there-
fore highly dependent on how patients are interviewed. This
notion underlines the problem of how to investigate a
drooling complaint: what do patients really mean when they
score the frequency of their drooling problem as ‘some-
times,’ ‘regularly,’ ‘often’ or ‘frequent?’ It is a well-known
psychometric problem that adjective scaling leads to high
variability in responses, because meanings of adjectives
differ depending on the context [18].
The results of the current review demonstrate that
research is required examining the prevalence and severity
of drooling in PD in more detail. We therefore suggest that
for future studies on drooling it is needed:
1. to report when drooling occurs: nocturnal or diurnal;
and if diurnal: while busy, or during daytime sleep
etcetera
2. to differentiate between feeling of accumulation of
saliva in the mouth and actual loss of saliva from the
mouth
3. to express the frequency in a countable manner, as in
times per day, less than once a day, etc.
These recommendations might also be used by clinicians
in order to evaluate possible worsening of drooling over
time, or to decide about the need for pharmacological or
non-pharmacological treatment. For example, when is a PD
patient eligible for treatment with botulinum toxin, or when
isbehavioraltreatmentbyaspeech-languagetherapistworth
trying ﬁrst? Although supportive evidence is lacking, in our
experience mild drooling complaints can be diminished by
practicing the usefulness of swallowing saliva before start-
ingtospeakorbeforestandingup,unlessapatientonlyloses
saliva during sleep or dozing off, which obviously cannot be
treated with voluntary adaptations. In many cases thorough
questioning is required to make this clear.
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